Ignite Creation Date:
2024-05-06 @ 7:28 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06028490
Status:
RECRUITING
Last Update Posted:
2023-09-11
First Post:
2023-08-31
Brief Title:
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis
Sponsor:
Zheng Liu ENT
Organization:
Tongji Hospital
Study Overview
Official Title:
The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment A Randomized Double-Blind Placebo-controlled Investigator Initiated Trial
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Allergic rhinitis AR is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals The typical symptoms of AR are paroxysmal sneezing watery rhinorrhea itching and nasal congestion which may be accompanied by ocular symptoms including eye itching tearing redness and burning sensation which are more common in patients with hay fever allergies Bronchial asthma is associated with bronchial asthma in 40 of patients with AR suggesting a comorbid feature of allergic disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None